Pramodini Medicare IPO - Company Analysis
Pramodini Medicare IPO under the SME IPO category is a book-built issue of Rs. 69.04 Cr by Pramodini Medicare Limited, which is a provider of technology-enabled diagnostic services in the fields of nuclear medicine, clinical laboratory, and radiology in India.
Microbiology, immunology, pathology, and biochemistry; nuclear medicine services like PET-CT, SPECT, and nuclear treatment; and radiology services like MRI, CT scans, X-rays, ultrasound with color Doppler, mammography, DEXA scan, and interventional radiology are all included in its service portfolio.
Model of Service
- Public-Private Partnership (PPP)
- Private-Private Partnership (Pvt-Pvt)
- Strategic Alliances with PSUs
- Standalone Diagnostic Centers
- Location-Specific Contracts.
Pramodini Medicare IPO Details
The Pramodini Medicare IPO date of opening is 12 Aug 2026; its initial public offering will end on 14 Aug, IPO allotment on Aug 17 and refund initiation on Aug 18, 2026.
The Rs. 69.04 crore new SME IPO comprises a fresh issue of 0.54 crore shares (Rs. 63.14 Cr) and an offer for sale of 0.05 crore shares (Rs. 5.90 Cr).
The Pramodini Medicare IPO listing date (expected) might be Wednesday, Aug 19, 2026, and the listing on the NSE and SME.
The Pramodini Medicare IPO price band is Rs. 110-118.
IPO Timetable (Tentative)
|
Events |
Date |
|
IPO Opening Date |
Aug 12, 2026 |
|
IPO Closing Date |
Aug 14, 2026 |
|
IPO Allotment Date |
Aug 17, 2026 |
|
Refund Initiation |
Aug 18, 2026 |
|
IPO Listing Date |
Aug 19, 2026 |
Click to open demat account and apply for the IPO.
Company Financials
(Amount in Cr)
|
Particulars |
31 Mar 2026 |
31 Mar 2025 |
31 Mar 2024 |
|
Assets |
93.62 |
56.45 |
48.78 |
|
Total Income |
63.38 |
38.55 |
35.79 |
|
Profit After Tax |
17.38 |
11.14 |
7.14 |
|
EBITDA |
30.90 |
20.97 |
15.53 |
|
Net Worth |
53.15 |
35.77 |
24.75 |
|
Reserves and Surplus |
36.46 |
34.49 |
23.46 |
|
Total Borrowing |
17.85 |
10.81 |
11.96 |
Cash Flows
(Amount in lac)
|
Net Cash Flow |
31 Mar 2026 |
31 Mar 2025 |
31 Mar 2024 |
|
Net Cash Flow Operating Activities |
2,539.05 |
2,212.13 |
985.36 |
|
Net Cash Flow Investing Activities |
(3,062.67) |
(1,445.58) |
(138.13) |
|
Net Cash Flow Financing Activities |
573.17 |
(239.10) |
(1,081.00) |
Revenue Bifurcation
(Rs. in Lac)
(Source: RHP)
The Objective of the Issue
The Company desires to use the Net Proceeds from the Issue to fulfill its following goals:
-
Funding of capital expenditure for purchase of Medical Equipment towards Existing and Proposed Diagnostic Centres. ~ Rs. 45.15 Cr.
-
General Corporate Purposes.
Listed Peers of Pramodini Medicare Ltd.
|
Name of Company |
Face Value (Rs. ) |
Basic EPS (Rs. ) |
PE Ratio (x) |
|
Invicta Diagnostic Limited |
10 |
4.90 |
13.62 |
|
Krsnaa Diagnostics Limited |
5 |
31.30 |
16.74 |
|
Star Imaging & Path Labs Limited |
10 |
11.05 |
7.87 |
Valuation
|
KPI |
Value (Mar 31, 2026) |
|
ROE |
39.08% |
|
ROCE |
34.66% |
|
Debt/Equity |
0.34 |
|
RoNW |
32.69% |
|
PAT Margin |
27.90 |
|
EBITDA Margin |
49.61% |
Evaluation of P/E Ratio
Considering the period ended on FY 2026 with an EPS of Rs. 10.41 from the last year, the resulting P/E ratio is 11.33x.
Explore the Optimystix Entertainment IPO.
IPO's Strengths
-
Establishing a strategic presence across various states of India.
-
Strengthening its network through diversified business models.
-
Strong technical capabilities supported by robust IT infrastructure.
-
Experienced management team with significant industry expertise.
IPO's Weaknesses
-
Dependence on government PPP contracts
-
High reliance on radiology services
-
Geographical concentration risk.
Pramodini Medicare IPO GMP
Pramodini Medicare IPO GMP today is Rs. 0 as of 10 August 2026, while writing this information.
Pramodini Medicare IPO Summary
|
IPO Opening & Closing Date |
12 Aug, 2026 to 14 Aug, 2026 |
|
Face Value |
Rs. 10 per Share |
|
Issue Price |
Rs. 110 to Rs. 118 per Share. |
|
Lot Size |
1200 Shares |
|
Issue Size |
58,51,200 Shares (Rs. 69 Cr) |
|
Offer for Sale |
5,00,400 Shares (Rs. 6 Cr) |
|
Fresh Issue |
50,14,800 Shares (Rs. 59 Cr) |
|
Listing at |
NSE, SME |
|
Issue Type |
Book-build Issue |
|
Registrar |
Purva Sharegistry (India) Pvt. Ltd. |
IPO Lot Details
Retail investors can invest in a minimum and maximum of 2 Lots (2400 Shares) for Rs. 2,83,200, and in multiples thereof, while HNI investors can invest in a minimum of 3 Lots (3600 Shares) for Rs. 4,24,800.
|
Minimum Lot Investment (Retail) |
2 Lots |
|
Maximum Lot Investment (Retail) |
2 Lots |
|
HNI (Min) |
3 Lots |
Pramodini Medicare IPO Allotment Status
To check the Pramodini Medicare IPO Allotment Status, visit the official Registrar’s website or BSE website. Below are the website links for you.
Using BSE Website - BSE IPO allotment status
Promoters And Management of Pramodini Medicare Ltd.
-
Chalasani Kuldeep Kumar
-
Chalasani Kavitha
-
Chalasani Durga Aashritha
-
Chalasani Lalithakumar
-
Sri Ram Medicare Pvt. Ltd.
|
Pre-Issue Promoter Shareholding |
85.71% |
|
Post-Issue Promoter Shareholding |
62.64% |
IPO Lead Managers
- Smart Horizon Capital Advisors Pvt. Ltd.
Dividend Policy
The company has not paid a dividend during the last three FYs.
Conclusion
Pramodini Medicare IPO offers investors exposure to India’s growing diagnostic healthcare sector, supported by strong revenue growth, improving profitability, and a diversified service model.
The company’s expansion plans, healthy margins, and presence across PPP and private diagnostic networks are key positives, while contract dependency and geographic concentration remain important risks.
Other Related Blogs:-
Gulf Lloyds IPO
Finowings IPO Analysis
Hope you enjoyed the Finowings IPO Analysis. We tried our best to provide all the required details about the company you should know before applying for the IPO.
You must consult your financial advisor before making any financial decisions.
To Apply for the IPO, Click Here.
To read the Prospectus of the company, click here to download the DRHP.
Click Here To Stay Updated With The Upcoming IPOs.
DISCLAIMER: This blog is NOT any buy or sell recommendation. No investment or trading advice is given. The content is purely for educational and information purposes only. Always consult your eligible financial advisor for investment-related decisions.
